Analyzing the trends and forecasting Global Lung Cancer Therapeutics Analyzing the trends and forecasting Global Lung C | Page 3

 Navelbine
 Camptosar
 Alimta
2) Radiotherapy
 External Beam
 Internal Beam
 Systemic
3) Other Drugs
 Abraxane
 Avastin
 Crizotinib
 Docetaxel
 Gefitinib
Based on geography the market is analysed under various regions namely, North America,
Latin America, Europe, Asia-Pacific and Middle-East & Africa. North America and Europe
leads the global lung cancer therapeutics market. Lung cancer is the most common type of
cancer in U.S and majority of population die of lung cancer every year. Asia-Pacific countries
such as India and China are the developing regions for the global lung cancer therapeutics
market owing to high occurrence of this disease along with growing healthcare alertness.





North America Lung Cancer Therapeutics Market
Europe Lung Cancer Therapeutics Market
Asia-Pacific Lung Cancer Therapeutics Market
Latin America Lung Cancer Therapeutics Market
Middle East and Africa Lung Cancer Therapeutics Market
Companies are implementing various strategies to increase their product portfolio and rise its
geographical presence. New product expansion, contracts and associations and procurements are
some of the significant approaches adopted by the manufacturers in the lung cancer therapeutics
market. The prominent players of this market include BoehringerIngelheim GmbH, Hoffman-La
Roche, Pfizer Inc., GlaxoSmitKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-
Aventis.
The Lung Cancer Therapeutics Market study offers the following deliverables:

Global, regional and country-level analysis and forecasts of the study market;
providing Insights on the geographical areas in which this industry is blooming